VR to Reduce Pain and Anxiety During GU Scans
Primary Purpose
Urologic Diseases, Urogenital Disease, Vesico-Ureteral Reflux
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Oculus Go VR
Sponsored by
About this trial
This is an interventional supportive care trial for Urologic Diseases focused on measuring virtual reality, voiding cystourethrogram, catheterization
Eligibility Criteria
Inclusion criteria for children:
- Children who are 5-21 years old
- Children who are English or Spanish speaking.
- Children undergoing a VCUG at CHLA.
- Only children who are in the normal range of development will be recruited for this study. This will be assessed by report from the parents. The rationale for excluding patients with developmental delay is that due to their cognitive impairments, such children react to the stressors of medical procedures differently than do children without such developmental delay. It is unclear how such children would use the interventions included in this study, and it is likely that their responses on baseline and outcome measures will differ from children of normal developmental parameters.
Inclusion criteria for caregivers (no age limits):
- Have a child who is undergoing a VCUG at CHLA.
- Caregiver is present during the child's VCUG.
- Caregiver is English or Spanish speaking.
- Caregiver is 18 years old or older.
Inclusion criteria for healthcare providers (no age limits):
- Provider is 18 years old or older
- Provider is a CHLA employee.
- Provider may participate if he/she witnessed and/or administered the medical procedure.
Exclusion Criteria:
- Child is currently taking pain medication or anxiolytic medication, including midazolam
- Child has a psychiatric disorder (i.e. anxiety, psychotic, thought disorder), organic brain syndrome, intellectual disability, Autism Spectrum Disorder, or other known cognitive/neurological disorder
- Child has visual, auditory, or tactile deficit that would interfere with the ability to complete the experimental tasks
- Child has a history of seizure disorder
- Child is currently sick with flu-like symptoms or experiencing a headache or earache
- Child has known or suspected motion sickness
- Child catheterizes regularly or has an insensate urethra
- Languages other than English and Spanish will be excluded given that the proposed measures have not been standardized for use in other languages.
Sites / Locations
- Children's Hospital Los Angeles
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Standard of Care (No VR) Randomization
VR Randomization
Arm Description
Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.
Patients will receive virtual reality in addition to standard of care.
Outcomes
Primary Outcome Measures
Change in Pain during VCUG - Pain Visual Analog Scale
Participant levels of pain will be assessed using the Pain Visual Analog Scale (min. score = 0; max. score = 100. Higher score = higher pain)
Secondary Outcome Measures
Change in Pain during VCUG - Faces Pain Scale-Revised
Participant levels of pain will be assessed using the Faces Pain Scale-Revised (min. score = 0; max. score = 10. Higher score = higher pain)
Change in Pain during VCUG - Colored Analog Scale
Participant levels of pain will be assessed using the Colored Analog Scale (min. score = 0; max. score = 10. Higher score = higher pain)
Change in Anxiety during VCUG - Procedural Anxiety Visual Analog Scale
Participant levels of anxiety will be assessed using the Procedural Anxiety Visual Analog Scale (min. score = 0; max. score = 10. Higher score = higher anxiety)
Change in Anxiety during VCUG - Facial Affective Scale
Participant levels of anxiety will be assessed using the Facial Affective Scale (min. score = 0; max. score = 1. Higher score = higher anxiety)
Baseline Anxiety before VCUG - Anxiety Sensitivity Index
Participant baseline anxiety will be assessed using the Anxiety Sensitivity Index, a 16-item questionnaire (min. score = 0; max. score = 64. Higher score = higher anxiety sensitivity; i.e. higher dispositional tendency to fear the somatic and cognitive symptoms of anxiety due to a belief that these symptoms may be dangerous or harmful).
Satisfaction with VR
Participant satisfaction with VR assessed using a 10-item satisfaction survey (min. score = 0; max. score = 50. Higher score = higher satisfaction).
Full Information
NCT ID
NCT04251988
First Posted
January 23, 2020
Last Updated
June 13, 2023
Sponsor
Children's Hospital Los Angeles
1. Study Identification
Unique Protocol Identification Number
NCT04251988
Brief Title
VR to Reduce Pain and Anxiety During GU Scans
Official Title
The Effectiveness of Virtual Reality (VR) to Reduce Pain and Anxiety During Genitourinary (GU) Scans
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 15, 2020 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Children's Hospital Los Angeles
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
This study aims to test the effectiveness of virtual reality (VR) in reducing pain and anxiety in children undergoing voiding cystourethrograms (VCUG) at Children's Hospital Los Angeles (CHLA). A voiding cystourethrogram is a genitourinary diagnostic scan that provides important urological information, specifically the filling and releasing of the bladder. This information can help diagnose urological issues in children. However, this procedure requires catheterization, which is understood to be a painful and anxiety-provoking procedure. This study will test the effectiveness of VR as a non-pharmaceutical intervention to relieve pain and anxiety in pediatric patients undergoing VCUGs.
Detailed Description
Background: VCUGs are genitourinary diagnostic scans that provide valuable medical information for pediatric patients with urological issues. However, these scans require catheterization, which can be anxiety-provoking, painful, and in some cases traumatic. Previous studies have assessed the use of pharmacological agents to address pain and anxiety during these procedures, but few studies exist examining non-pharmacological interventions in a methodologically rigorous way. As pharmacological interventions are associated with numerous side effects, and may not be appropriate for all pediatric patients, effective non-pharmacological interventions are needed for patients undergoing VCUGs.
Aims: This study aims to determine the effectiveness of virtual reality (VR) in reducing pain and anxiety among children undergoing VCUGs at CHLA. This study will also assess patient, parent, and provider satisfaction with VR, and ease of completing VCUGs using VR vs. the standard of care.
Study Population: CHLA patients aged 5-21 years receiving VCUGs at CHLA. Methods: A stratified randomization scheme will be used to assign patients aged 5-21 undergoing VCUG scans to receive the standard of care (i.e. caregiver presence in the room and Child Life Specialists in the room if desired), or the standard of care plus VR. Individuals assigned to the VR arm will be fitted with a Samsung head-tracking system, and will play an AppliedVR game prior to and during catheterization. Standardized questionnaires will be administered to patients and caregivers before and after the procedure to measure pain and anxiety. Satisfaction questionnaires will be administered post-procedure.
Significance: VR is a non-invasive intervention that, if effective, could become part of a standard protocol to reduce pain and anxiety among children undergoing VCUGs. As there is a dearth of knowledge regarding non-pharmacologic interventions for children receiving VCUGs, this study will provide a foundation to inform future research on VR use among pediatric urology patients.
See 'References' for Brief Summary References
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urologic Diseases, Urogenital Disease, Vesico-Ureteral Reflux
Keywords
virtual reality, voiding cystourethrogram, catheterization
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
410 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard of Care (No VR) Randomization
Arm Type
No Intervention
Arm Description
Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.
Arm Title
VR Randomization
Arm Type
Experimental
Arm Description
Patients will receive virtual reality in addition to standard of care.
Intervention Type
Device
Intervention Name(s)
Oculus Go VR
Intervention Description
virtual reality headset
Primary Outcome Measure Information:
Title
Change in Pain during VCUG - Pain Visual Analog Scale
Description
Participant levels of pain will be assessed using the Pain Visual Analog Scale (min. score = 0; max. score = 100. Higher score = higher pain)
Time Frame
Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.
Secondary Outcome Measure Information:
Title
Change in Pain during VCUG - Faces Pain Scale-Revised
Description
Participant levels of pain will be assessed using the Faces Pain Scale-Revised (min. score = 0; max. score = 10. Higher score = higher pain)
Time Frame
Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.
Title
Change in Pain during VCUG - Colored Analog Scale
Description
Participant levels of pain will be assessed using the Colored Analog Scale (min. score = 0; max. score = 10. Higher score = higher pain)
Time Frame
Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.
Title
Change in Anxiety during VCUG - Procedural Anxiety Visual Analog Scale
Description
Participant levels of anxiety will be assessed using the Procedural Anxiety Visual Analog Scale (min. score = 0; max. score = 10. Higher score = higher anxiety)
Time Frame
Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.
Title
Change in Anxiety during VCUG - Facial Affective Scale
Description
Participant levels of anxiety will be assessed using the Facial Affective Scale (min. score = 0; max. score = 1. Higher score = higher anxiety)
Time Frame
Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.
Title
Baseline Anxiety before VCUG - Anxiety Sensitivity Index
Description
Participant baseline anxiety will be assessed using the Anxiety Sensitivity Index, a 16-item questionnaire (min. score = 0; max. score = 64. Higher score = higher anxiety sensitivity; i.e. higher dispositional tendency to fear the somatic and cognitive symptoms of anxiety due to a belief that these symptoms may be dangerous or harmful).
Time Frame
Will be administered to participants approximately 20 minutes before the start of the VCUG.
Title
Satisfaction with VR
Description
Participant satisfaction with VR assessed using a 10-item satisfaction survey (min. score = 0; max. score = 50. Higher score = higher satisfaction).
Time Frame
Questionnaires will be administered to participants within 15 minutes following the end of the VCUG.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for children:
Children who are 5-21 years old
Children who are English or Spanish speaking.
Children undergoing a VCUG at CHLA.
Only children who are in the normal range of development will be recruited for this study. This will be assessed by report from the parents. The rationale for excluding patients with developmental delay is that due to their cognitive impairments, such children react to the stressors of medical procedures differently than do children without such developmental delay. It is unclear how such children would use the interventions included in this study, and it is likely that their responses on baseline and outcome measures will differ from children of normal developmental parameters.
Inclusion criteria for caregivers (no age limits):
Have a child who is undergoing a VCUG at CHLA.
Caregiver is present during the child's VCUG.
Caregiver is English or Spanish speaking.
Caregiver is 18 years old or older.
Inclusion criteria for healthcare providers (no age limits):
Provider is 18 years old or older
Provider is a CHLA employee.
Provider may participate if he/she witnessed and/or administered the medical procedure.
Exclusion Criteria:
Child is currently taking pain medication or anxiolytic medication, including midazolam
Child has a psychiatric disorder (i.e. anxiety, psychotic, thought disorder), organic brain syndrome, intellectual disability, Autism Spectrum Disorder, or other known cognitive/neurological disorder
Child has visual, auditory, or tactile deficit that would interfere with the ability to complete the experimental tasks
Child has a history of seizure disorder
Child is currently sick with flu-like symptoms or experiencing a headache or earache
Child has known or suspected motion sickness
Child catheterizes regularly or has an insensate urethra
Languages other than English and Spanish will be excluded given that the proposed measures have not been standardized for use in other languages.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andy M Chang, MD
Organizational Affiliation
Children's Hospital Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
22763832
Citation
Alexander M. Managing patient stress in pediatric radiology. Radiol Technol. 2012 Jul-Aug;83(6):549-60.
Results Reference
background
PubMed Identifier
27931463
Citation
Guideline for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures: Update 2016. Pediatr Dent. 2016 Oct;38(6):216-245.
Results Reference
background
PubMed Identifier
3810213
Citation
Glazer JD, Benrubi GI, Nuss RC. Positive results of endocervical curettage as an indication for conization of the cervix. South Med J. 1987 Feb;80(2):185-6. doi: 10.1097/00007611-198702000-00011.
Results Reference
background
PubMed Identifier
10196917
Citation
Stashinko EE, Goldberger J. Test or trauma? The voiding cystourethrogram experience of young children. Issues Compr Pediatr Nurs. 1998 Apr-Jun;21(2):85-96. doi: 10.1080/014608698265519.
Results Reference
background
Learn more about this trial
VR to Reduce Pain and Anxiety During GU Scans
We'll reach out to this number within 24 hrs